Taken together, our findings may provide a cellular and molecular mechanism for UB as a promising candidate medication on RANKL‐mediated osteoclast differentiation and bone loss diseases, such as osteoporosis and osteolysis. The gene discussed is TNFSF11; the disease is osteoporosis.